Sign In
Buy VERU
$2.77
+0.440 (+18.88%)
At Close: Aug 10, 2026
Flora Growth (NASDAQ:FLGC) and Veru (NASDAQ:VERU) Financial Review
01:32am, Sunday, 08'th Feb 2026
Veru (NASDAQ: VERU - Get Free Report) and Flora Growth (NASDAQ: FLGC - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th
08:30am, Wednesday, 04'th Feb 2026
MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a
Veru Inc. (VERU) Q4 2025 Earnings Call Transcript
11:59am, Wednesday, 17'th Dec 2025
Veru Inc. (VERU) Q4 2025 Earnings Call Transcript
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress
06:30am, Wednesday, 17'th Dec 2025
MIAMI, FL, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a
Veru (NASDAQ:VERU) Share Price Crosses Below Two Hundred Day Moving Average – Here’s Why
05:30am, Tuesday, 16'th Dec 2025
Veru Inc. (NASDAQ: VERU - Get Free Report) shares passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $4.16 and traded as low as $2.38. Veru sha
Veru to Report Fiscal Year 2025 Financial Results on December 17th
08:30am, Wednesday, 10'th Dec 2025
MIAMI, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a
Veru to Present Two Abstracts at ObesityWeek 2025
08:30am, Friday, 31'st Oct 2025
MIAMI, FL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a
Veru Announces Proposed Public Offering
04:01pm, Wednesday, 29'th Oct 2025
MIAMI, FL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a
MIAMI, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic
Veru Announces Novel Modified-Release Oral Formulation for Enobosarm
10:21am, Friday, 15'th Aug 2025
VERU unveils a novel modified-release oral enobosarm to enhance fat loss while preserving lean mass in chronic weight loss management.
Veru Inc. (VERU) Q3 2025 Earnings Call Transcript
12:57pm, Tuesday, 12'th Aug 2025
Veru Inc. (NASDAQ:VERU ) Q3 2025 Earnings Call August 12, 2025 8:00 AM ET Company Participants K. Gary Barnette - Chief Scientific Officer Michael J.
Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress
06:30am, Tuesday, 12'th Aug 2025
--Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal side
MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and i
Veru Announces Reverse Stock Split
08:30am, Wednesday, 06'th Aug 2025
MIAMI, FL, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a
Veru to Participate in the 2025 BTIG Virtual Biotech Conference
08:30am, Tuesday, 22'nd Jul 2025
MIAMI, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a
